Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months-Reference-Cited by-同舟云学术

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months

Published:2016-02 Issue:2 Volume:26 Page:378-389
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Kennedy Sidney H.,Avedisova Alla,Belaïdi Carole,Picarel-Blanchot Françoise,de Bodinat Christian

Funder

Anna Cyriac

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology

Reference27 articles.

1. Diagnostic and Statistical Manual of Mental Disorders;American Psychiatric Association,2000

2. Efficacy and safety of levomilnacipran sustained release 40mg, 80mg, or 120mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study;Asnis;J. Clin. Psychiatry,2013

3. A validation analysis of two self-reported HAM-D6 versions;Bech;Acta Psychiatr. Scand.,2009

4. Major depressive disorder treatment guidelines in America and Europe;Davidson;J. Clin. Psychiatry,2010

5. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development;de Bodinat;Nat. Rev. Drug Discov.,2010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations of adolescent substance use and depressive symptoms with adult major depressive disorder in the United States: NSDUH 2016–2019;Journal of Affective Disorders;2024-01

2. Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis;Medicine;2023-11-10

3. Diagnosis and treatment of depression according to the functional recovery paradigm;Neurology, Neuropsychiatry, Psychosomatics;2023-10-23

4. Practical pathway for the management of depression in the workplace: a Canadian perspective;Frontiers in Psychiatry;2023-09-05

5. Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting;Clinical Psychopharmacology and Neuroscience;2023-08-31